CollPlant Biotechnologies Announces $2.6 Million Private Placement

CollPlant Biotechnologies announced in a press release that it has entered into a definitive agreement for a private placement totaling approximately 7,647,061 ordinary shares and unregistered warrants. The combined purchase price is $0.34 per share and accompanying warrants, with gross proceeds expected to reach about $2.6 million before fees and expenses.

The placement includes series A warrants to purchase up to 7,647,061 shares and series B warrants for up to 15,294,122 shares. Both series will have an exercise price of $0.34 per share and will become exercisable upon shareholder approval. The series A warrants will expire two years after registration effectiveness, while the series B warrants will expire five years after.

The transaction, managed by H.C. Wainwright & Co. as exclusive placement agent, is expected to close on or about July 1, 2026, subject to customary conditions. CollPlant stated that proceeds would be used for general corporate purposes, working capital, and ongoing research programs. The company also plans to continue evaluating strategic business combinations such as acquisitions or joint ventures.